Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the use of intravenous tenecteplase for patients with acute ischemic stroke AIS. This trial aims to determine the best dose of tenecteplasestandard-dose 0.25 mgkg versus low-dose 0.18 mgkgand whether to use tenecteplase or no thrombolysis in specific patient groups, including those recently using direct oral anticoagulants DOACs and those planned for emergency endovascular thrombectomy EVT. The study addresses uncertainties in dosing and safety for various patient subgroups, such as the elderly, patients with comorbidities, and those with different brain imaging findings. Participants will be randomly assigned to receive either standard-dose or low-dose tenecteplase as a single intravenous bolus, or no tenecteplase if they are on recent DOACs or planned for EVT. The doses are administered quickly after randomization. The trial compares these approaches to find the most effective and safe use of tenecteplase for AIS treatment. The study follows participants for 90 days after treatment to assess outcomes. During the study, researchers will assess participants functional independence using the modified Rankin Scale at 90 days, along with mortality, quality of life, and imaging outcomes. Safety events like intracranial hemorrhage and serious adverse events will be monitored closely, especially within the first days after treatment. Participants will have assessments including telephone follow-ups, hospital discharge status, and brain imaging evaluations. The total participation lasts up to 90 days or until death if earlier.
Actively Recruiting
The trial focuses on moderate and late preterm infants born between 32 and 36 weeks gestation who are admitted to Level 2 and 3 Neonatal Intensive Care Units NICUs across Alberta. Researchers aim to find out if applying collaborative quality improvement methods and standardized care bundles can reduce the length of hospital stays and help babies get home faster. This stepped-wedge cluster randomized trial includes 12 NICUs randomized to adopt the intervention at different times, allowing comparison against current standard care. The intervention involves multiple collaborative quality improvement strategies building dedicated QI teams in each NICU, providing standardized QI education, implementing two care bundles focused on respiratory and nutritional support, mentoring by experienced QI members, and facilitating collaborative networking with regular virtual and in-person meetings. Participating NICUs will transition from current practices to this intervention in phases over three years. During the control period, NICUs continue their usual care and any ongoing QI activities without the new intervention strategies. Participants progress will be monitored from birth until discharge or death, with assessments continuing up to six months after their due date. Researchers will track hospital stay length, healthcare costs, respiratory support duration, feeding milestones, growth measurements, rehospitalizations, mortality, and staff perceptions of QI implementation. Data will be collected through clinical records and surveys. The study spans from May 2023 to August 2027, aiming to improve care quality and outcomes for these preterm infants.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.